Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience

Pediatric Infectious Disease Journal

Volumn 15, Issue 11, 1996, Pages 967-979

  Kirsch, Erica A ^a   Barton, R Phillip ^a   Kitchen, Louann ^a   Giroir, Brett P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

bactericidal permeability increasing protein; bactericidal permeability increasing protein; cytokines; endotoxin; meningitis; Meningococcemia; sepsis; septic shock

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; PENICILLIN G;

ANTIBIOTIC THERAPY; HUMAN; INFECTION PREVENTION; INFECTION RISK; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

BACTEREMIA; HUMANS; MENINGOCOCCAL INFECTIONS; PROGNOSIS;

EID: 0029825302     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199611000-00009     Document Type: Review

References (133)

1. Reido FX, Plikaytis BD, Broome CV. Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J 1995;14:643-57.
2. 1994 Red Book: report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 1994:323-6.
3. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 1984;63:243-73.
4. Orren A, Potter PC, Cooper RC, du Toit E. Deficiency of the sixth component of complement and susceptibility to Neisseria meningitidis infections: studies in 10 families and five isolated cases. Immunology 1987;62:249-53.
5. Moore PS, Broome CV. Cerebrospinal meningitis epidemics. Sci Am 1994:38-45.
6. Steven N, Wood M. The clinical spectrum of meningococcal disease. In: Meningococcal disease. Chichester, UK: Wiley, 1995:177-205.
7. Van Deuren M, van Dijke BJ, Koopman RJJ, et al. Br Med J 1993;306:1229-32.
8. Stephens DS, Farley MM. Pathogenic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae. Rev Infect Dis 1991;13:22-3.
9. Young LS, LaForce FM, Head JJ, Feeley JC, Bennett JV. A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med 1972;287:5-9.
10. Moore PS, Hierholzer J, DeWitt W, et al. Respiratory viruses and Mycoplasma as cofactors for epidemic Group A meningococcal meningitis. JAMA 1990;264:1271-5.
11. Cartwright KAV, Jones DM, Smith AJ, Stuart JM, Kaczmarski EB, Palmer SR. Influenza A and meningococcal disease. Lancet 1991;338:554-7.
12. Hubert B, Watier L, Garnerin P, Richardson S. Meningococcal disease and influenza-like syndrome: a new approach to an old question. J Infect Dis 1992;166:542-5.
13. Hannenberg B, Tonjum T, Rodahl K, Gedde-Dahl TW. Factors preceding the onset of meningococcal disease with special emphasis on passive smoking, stressful events, physical fitness and general symptoms of ill health. NIPH Ann 1983;6:169-73.
14. Jarvis GA, Vedros NA. Sialic acid of Group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun 1987;55:174-80.
15. Griffiss JM. Mechanisms of host immunity. In: Cartwright K, ed. Meningococcal disease. Chichester, UK: Wiley, 1995: 35-70.
16. Poolman JT, van der Ley PA, Tommassen J. Surface structures and secreted products of meningococci. In: Cartwright K, ed. Meningococcal disease. Chichester, UK: Wiley, 1995: 21-34.
17. Brandtzaeg P, Kierulf P, Gaustad P, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989;159:195-204.
18. Brandtzaeg P, Mollnes TE, Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 1989;160:58-65.
19. Brandtzaeg P, Halstensen A, Kierulf P, Espevik T, Waage A. Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock. Microb Pathog 1992;13:423-32.
20. Frank MM, Joiner K, Hammer C. The function of antibodies and complement in the lysis of bacteria. Rev Infect Dis 1987;9:S537-45.
21. van Deventer SJH, Buller HR, ten Cate JW, Aarden LA, Hack E, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520-6.
22. Osterud B, Faegstad T. Increased tissue thromboplastic activity in monocytes of patients with meningococcal infections related to unfavourable prognosis. Thromb Haemost 1983;49:5-7.
23. Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989;53:231-41.
24. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983;71:1893-6.
25. Eley B, Levin M. Septic shock with special reference to meningococcal disease. Curr Opin Infect Dis 1994;7:345-50.
26. van Deuren M, van der Ven-Jongekrijg J, Demacker PN, et al. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 1994;169:157-61.
27. van Deuren M, van der Ven-Jongekrijg J, Bartelink AKM, van Dalen R, Sauerwein RW, van der Meer JWM. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 1995;172:433-9.
28. Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995;63: 2109-12.
29. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S. High levels of interleukin 10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995; 171:229-32.
30. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-7.
31. Waage A, Brandtzaeg F, Halstensen A, Kierulf P, Espevik T. The complex pattern of Cytokines in Serum from patients with meningococcal septic shock. J Exp Med 1989;169: 333-8.
32. Girardin E, Grau GE, Dayer J, Roux-Lombard P, Lambert P. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988;319:397-400.
33. Westendorp RGJ, Langermans JAM, de Bel CE, et al. Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J Infect Dis 1995;171:1057-60.
34. Waring PM, Waring LJ, Metcalf D. Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia. J Infect Dis 1994;170:1224-8.
35. Brandtzaeg P. Pathogenesis of meningococcal infections. In: Cartwright K, ed. Meningococcal disease. Chichester, UK: Wiley, 1995:71-114.
36. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988;8:5588-92.
37. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-5.
38. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989;320:1165-72.
39. Levi M, ten Cate H, van der Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975-9.
40. Brandtzaeg P, Sandset PM, Joo GB, Ovstebo R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989;55:459-70.
41. Fourrier F, Lestavel P, Chopin C, et al. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 1990;16:121-4.
42. Fijnvandraat K, Derkx B, Peters M, et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995;73:15-20.
43. Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest 1991;21: 361-74.
44. Nadel S, Levin M, Habibi P. Treatment of meningococcal disease in childhood. In: Meningococcal disease. West Sussex, UK: Wiley, 1995:207-43.
45. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-77.
46. Waage A, Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J Exp Med 1988;167:1987-92.
47. Villard J, Roux-Lombare P, Hugli A, Dayer J. Could natural inhibitors of tumor necrosis factor-alpha modify the clinical course of fulminant meningococcemia? Crit Care Med 1993; 21:1396-400.
48. Lewis LS. Prognostic factors in acute meningococcaemia. Arch Dis Child 1979;45:44-48.
49. Bjorvatn B, Bjertnaes L, Fadnes HO, et al. Meningococcal septicaemia treated with combined plasmapheresis and leukapheresis or with blood exchange. Br Med J 1984;288:439-41.
50. van Deuren M, Santman FW, van Dalen R, Sauerwein RW, Span LFR, van der Meer JWM. Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 1992;15: 424-30.
51. Manios SG, Kanakoudi F, Maniati E. Fulminant meningococcemia; heparin therapy and survival rate. Scand J infect Dis 1971;3:127-33.
52. Boucek MM, Boerth RC, Artman M, Graham TP, Boucek RJ. Myocardial dysfunction in children with acute meningococcemia. J Pediatr 1984;105:538-42.
53. Mercier JC, Beaufils F, Hartman JF, Azema D. Hemodynamic patterns of meningococcal shock in children. Crit Care Med 1988;16:27-33.
54. Heyderman RS, Klein NJ, Shennan GI, Levin M. Deficiency of prostacyclin production in meningococcal shock. Arch Dis Child 1991;66:1296-9.
55. Landy SJ, McGavin CR. Dressler's syndrome after meningococcal myopericarditis. Respir Med 1990;84:415-6.
56. Hardman JM, Earle KM. Myocarditis in 200 fatal meningococcal infections. Arch Pathol 1969;87:318-25.
57. Sandler MA, Pincus PS, Weltman MD, et al. Meningococcaemia complicated by myocarditis. S Afr Med J 1989;75: 391-3.
58. DaCosta DF, Neville E, Raman GV. Association of myocarditis and acute renal failure complicating meningococcal septicaemia. J Infect 1991;22:259-61.
59. Monsalve F, Rucabado L, Salvador A, Bonastre J, Cunat J, Ruano M. Myocardial depression in septic shock caused by meningococcal infection. Crit Care Med 1984;12:1021-3.
60. Penny JL, Brace WJ, Kennedy RJ. Meningococcic pericarditis: a case report and review of the literature. Am J Cardiol 1966;18:281-5.
61. Furguson JH, Chapman OD. Fulminating meningococcic infections and the so-called Waterhouse-Friderichsen syndrome. Am J Pathol 1948:763-95.
62. Marzouk O, Thomson APJ, Sills JA, Hart CA, Harris F. Features and outcome in meningococcal disease presenting with a maculopapular rash. Arch Dis Child 1991;66:485-7.
63. Toews WH, Bass JW. Skin manifestations of meningococcal infection and immediate indicator of prognosis. Am J Dis Child 1974;127:173-6.
64. Grogan DP, Love SM, Ogden JA, Millar EA, Johnson LO. Chondro-osseous abnormalities after meningococcemia. J Bone Joint Surg Am 1989;71:920-8.
65. Herrera R, Hobar PC, Ginsburg CM. Surgical intervention for the complications of meningococcal-induced purpura fulminans. Pediatr Infect Dis J 1994;13:734-7.
66. Schaad UB. Arthritis in disease due to Neisseria meningitidis. Rev Infect Dis 1980;2:880-7.
67. Cartwright K, Reilly S, White D, Stuart J. Early treatment with parenteral penicillin in meningococcal disease. Br J Med 1992;305:143-7.
68. Strang JR, Pugh EJ. Meningococcal infections: reducing the case fatality rate by giving penicillin before admission to hospital. Br J Med 1992;305:141-3.
69. Odio CM, Faingezicht I, Paris M, et al. The beneficial effects of early dexamethasone administration in infants. N Engl J Med 1991;324:1525-31.
70. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis: results of two double-blind, placebo-controlled trials. N Engl J Med 1988;319: 964-71.
71. Wald E. US Meningitis Study Group. Dexamethasone for children with meningitis [Abstract 73]. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 11 to 14, 1992.
72. Schaad UB, Lips U, Gnehm HE, et al. Dexamethasone therapy for bacterial meningitis in children. Lancet 1993; 342:457-61.
73. Kennedy WA, Hoyt MJ, McCracken GH. The role of corticosteroid therapy in children with pneumococcal meningitis. Am J Dis Child 1991;145:1374-8.
74. Enriquez G, Lucaya J, Dominguez P, Aso C. Sonographic diagnosis of adrenal hemorrhage in patients with fulminant meningococcal septicemia. Acta Paediatr Scand 1990;79: 1255-8.
75. Siegel LM, Grinspoon SK, Garvey GJ, Bilezikian JP. Sepsis and adrenal function. Trends Endocrinol Metab 1994;5: 324-8.
76. Soni A, Pepper GM, Wyrwinski PM, et al. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 1995;98:266-71.
77. Immunization Practices Advisory Committee. Meningococcal vaccines. MMWR 1985;34:255-9.
78. Schwartz B, Al-Tobaiqi A, Al-Ruwais A, et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of Group A Neisseria meningitidis. Lancet 1988;1:1239-42.
79. Klein NJ, Heyderman RS, Levin M. Management of meningococcal infections. Br J Hosp Med 1993;50:42-9.
80. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 1993;42:1-18.
81. Peter G, Hall CB, Lepow ML, Phillips CF, eds. 1991 Red Book: report of Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 1991:323-6.
82. Aase A, Bjune G, Hoiby EA, Rosenqvist E, Pedersen AK, Michaelsen TE. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect Immun 1995;63:3531-6.
83. Bjune E, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against Group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
84. deMoraes JC, Perkins BA, Camargo MCC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-8.
85. Weiss J, Elsbach P, Olsen I. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 1978;253:2664-72.
86. Gazzano-Santoro H, Parent JB, Grinna L. High affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun 1992;60:4754-61.
87. Lambert L, Wong P, Hoppe P, et al. Recombinant bactericidal/permeability-increasing (rBPI) protein kills both Gram-positive and Gram-negative bacteria [Abstract C6]. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4 to 7, 1994.
88. 21 and antibiotic in the treatment of Gram-negative sepsis in conscious rabbits [Abstract B53]. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4 to 7, 1994.
89. Betz-Corradin S, Heumann D, and Gallay P. Bactericidal/permeability increasing protein inhibits induction of macrophage nitric oxide production by lipopolysaccharide. J Infect Dis 1994;169:105-11.
90. 23) inhibits soluble CD14-mediated LPS-induced endothelial adherence for human neutrophils. Shock 1994;2:1-6.
91. 21) inhibits complement activation by lipid A and rough bacteria [Abstract G64], Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4 to 7, 1994.
92. Ammons WS, Kung A. A recombinant amino terminal fragment of bactericidal/permeability increasing protein prevents hemodynamic responses to endotoxin. Circ Shock 1993;41:176-84.
93. Kohn FR, Ammons WS, Horwitz A, et al. Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability increasing protein in experimental endotoxemia. J Infect Dis 1993;168:1307-10.
94. Ammons WS, Kohn FR, Kung AHC. Protective effects of an N-terminal fragment of bactericidal/permeability increasing protein in rodent models of Gram-negative sepsis: role of bactericidal properties. J Infect Dis 1994;710:1473-82.
95. Ammons WS, Kohn FR, Kung AHC. Protective effects of an N-terminal fragment of bactericidal/permeability increasing protein in endotoxin and Gram negative sepsis. In: Morrison DC, Ryan JL, eds. Novel therapeutic strategies in the treatment of sepsis. New York: Dekker, 1996:55-70.
96. von der Mohlen MA, van Deventer SJ, Levi M, et al. Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). Blood 1995;85:3437-43.
97. Drapkin MS, Wisch JS. Gelfand JA, Cannon JG, Dinarello CA. Plasmapheresis for fulminant meningococcemia. Pediatr Infect Dis J 1989;8:399-400.
98. Westendorp RGJ, Brand A, Haanen J, van Hinsbergh VWM, et al. Leukaplasmapheresis in meningococcal septic shock. Am J Med 1992;92:577-8.
99. Scharfman WB. Tillotson JF, Taft EG, Wright E. Plasmapheresis for Meningococcemia with disseminated intravascular coagulation [Letter]. N Engl J Med 1979;300:1277-8.
100. Osterud B. Meningococcal septicemia: the use of plasmapheresis or blood exchange and how to detect severe endotoxin induced white cell activation. Scand J Clin Lab Invest 1985;45(Suppl 178):47-51.
101. Brandtzaeg P, Sirnes K, Folsland B, et al. Plasmapheresis in the treatment of severe meningococcal or pneumococcal septicaemia with DIG and fibrinolysis: preliminary data on eight patients. Scand J Clin Lab Invest 1985;45(Suppl 178):53-5.
102. van Deuren M, Santman FW, van Dalen R, Sauerwein RW, Span LFR, van der Meer JWM. Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 1992;15: 424-30.
103. Garlund B, Sjolin J, Nilsson A, Roll M, Wickerts C, Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995;172:296-301.
104. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of E. coli infusion in baboons. Circ Shock 1988;26:227-35.
105. Taylor FB, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-34.
106. Creasey AA, Chang ACK, Feigen L, Wun TC, Taylor FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1991;91:2850-60.
107. Zenz W, Muntean W, Gallistl S, Zobel G, Grubbauer HM. Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics 1995; 96:144-8.
108. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25.
109. Rivard GE, David M, Farell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995;126:646-52.
110. Manios SG, Kanakoudi F, Maniati E. Fulminant meningococcemia: heparin therapy and survival rate. Scand J Infect Dis 1971;3:127-33.
111. Kuppermann N, Inkelis S, Saladino R. The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans. Pediatr Infect Dis J 1994;13:867-73.
112. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood 1982;60:284-7.
113. Irazuzta J, McManus ML. Use of topically applied nitroglycerin in the treatment of purpura fulminans. J Pediatr 1990;117:993-5.
114. Anderson CT, Berde CB, Sethna NF, Pribaz JJ. Meningococcal purpura fulminans: treatment of vascular insufficiency in a 2-yr-old child with lumbar epidural sympathetic blockade. Anesthesiology 1989;71:463-4.
115. Tobias JD, Haun SE, Helfaie J, Nichols DJ. Use of continuous block to relieve lower-extremity ischemia caused by vasculitis in a child with meningococcemia. J Pediatr 1989; 115:1019-21.
116. Ansari BM, Davies DB, Boyce JMH. A comparative study of adverse factors in meningococcaemia and meningococcal meningitis. Postgrad Med J 1979;55:780-3.
117. Stokland T, Flaegstad T, Gutteberg TJ. A clinical score for the prediction of outcome of patients with meningococcal infection. Acta Paediatr Scand 1985;Suppl 322:12.
118. Tesoro LJ, Selbst SM. Factors affecting outcome in meningococcal infections. Am J Dis Child 1991;145:218-20.
119. Algren JT, Lal S, Cutliff SA, Richman BJ. Predictors of outcome in acute meningococcal infection in children. Crit Care Med 1993;21:447-53.
120. Havens PL, Garland JS, Brook MM, Dewitz BA, Stremski ES, Troshynski TJ. Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987. Pediatr Infect Dis J 1989;8:8-11.
121. Steim ER, Damrosch DS. Factors in the prognosis of meningococcal infection. J Pediatr 1966;68:457-67.
122. Niklasson P, Lundbergh P, Strandell T. Prognostic factors in meningococcal disease. Scand J Infect Dis 1971;3:17-25.
123. Gedde-Dahl TVV, Bjark P, Hoiby EA, Host JH, Bruun JN. Severity of meningococcal disease: assessment by factors and scores and implications for patient management. Rev Infect Dis 1990;12:973-92.
124. Brandtzaeg P, Skulberg A. Prognosis of meningococcal septicaemia [Letter]. Lancet 1987;2:862.
125. Sinclair JF, Skeoch CH, Hallworth D. Prognosis of meningococcal septicaemia [Letter]. Lancet 1987;2:38.
126. Kahn A, Blum D. Factors for poor prognosis in fulminating meningococcemia. Clin Pediatr 1978;17:680-7.
127. Riorden FAI, Marzouk O, Thomson APJ, Sills JA, Hary CA. The changing presentations of meningococcal disease. Eur J Pediatr 1995;154:472-4.
128. LeClerc F, Beuscart R, Guillois B, et al. Prognostic factors of severe infectious purpura in children. Intensive Care Med 1985;11:140-3.
129. Mok Q, Butt W. The outcome of children admitted to intensive care with meningococcal septicaemia. Intensive Care Med 1996;22:259-63.
130. McManus MM, Churchwell KB. Coagulopathy as a predictor of outcome in meningococcal sepsis and the systemic inflammatory response syndrome with purpura. Crit Care Med 1993;21:706-11.
131. LeClerc F, Hue V, Martinet A, Delepoulle F. Scoring systems for accurate prognosis of patients with meningococcal infections. Am J Dis Child 1991;145:1090-1.
132. Thomson APJ, Sills JA, Hart CA. Validation of the Glasgow meningococcal septicemia prognostic score: a 10-year retrospective survey. Crit Care Med 1991;19:26-30.
133. Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med 1988;16:1110-6.